Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,050 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cell Transfer Clear all

Conditions: Medication Adherence
Interventions: Adherence Counseling, General Health Counseling, Text Messages; Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Dilated Cardiomyopathy (DCM), Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
Interventions: Allogeneic Cardiosphere-Derived Cells (CDCs); Biological
Lead sponsor: Capricor Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pancreatic Neoplasms, Pancreatic Adenocarcinoma
Interventions: Hyperthermic intraperitoneal chemotherapy, Open pancreaticoduodenectomy, Gemcitabine; Procedure · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies
Interventions: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions; Drug
Lead sponsor: LaTonya J. Hickson; Other
Eligibility: 30 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Advanced Renal Cell Carcinoma
Interventions: Carevive software; Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, Ocular Melanoma, Uveal Melanoma, Iris Melanoma, Conjunctival Melanoma, Non-Cutaneous Melanoma
Interventions: TBio-4101, Cyclophosphamide, Fludarabine, Interleukin-2; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Warts, Warts Hand, Verruca
Interventions: CellFX Device; Device
Lead sponsor: Pulse Biosciences, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Scottsdale, Arizona • San Diego, California • Rochester, New York + 2 more

Conditions: HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive, Unresectable Malignant Neoplasm, Sarcoma
Interventions: 18F-FHBG, Aldesleukin, Busulfan, Cellular Therapy, Computed Tomography, Filgrastim, Fludarabine, Leukapheresis, Plerixafor, Positron Emission Tomography; Other · Biological · Drug + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Vaccinia, Virus Diseases
Interventions: JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection, Phlebotomy, Research bronchoscopy, Skin punch biopsy, Bone marrow aspiration; Biological · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diffuse Intrinsic Pontine Glioma
Interventions: Tumor Lysate Vaccine, Imiquimod, Radiation therapy; Biological · Drug · Radiation
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 3 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Immunity Disorders, Aging, Inflammation
Interventions: HTB Rejuvenate; Dietary Supplement
Lead sponsor: Big Bold Health, PBC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Bainbridge Island, Washington

Conditions: Chronic Kidney Diseases
Interventions: Allogeneic adipose-derived mesenchymal stem cells (MSC); Drug
Lead sponsor: LaTonya J. Hickson; Other
Eligibility: 30 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Diabetes, Obesity, Metabolic Syndrome, Cardiovascular Disease
Interventions: Carbohydrate + Protein, Carbohydrate + Fat, Fiber, Carbohydrate load; Other
Lead sponsor: Tufts University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions: Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs), Placebo; Biological
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 90 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Advanced Cancers, Leukemia
Interventions: Leukapheresis, Fludarabine, Cyclophosphamide, T-cell Infusion; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fibroadenoma, Breast Cancer Stage I
Interventions: Harmonic motion imaging guided focused ultrasound (HMIgFUS), Microbubble-mediated Low Intensity Focused Ultrasound (LIFU), Microbubbles; Procedure · Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma
Interventions: Cyclophosphamide, Ciltacabtagene Autoleucel, Total body irradiation; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Interventions: GVAX, Placebo Vaccine, Allogeneic Hematopoietic Stem Cell Transplant, Busulfan, Fludarabine, Tacrolimus, Methotrexate; Biological · Procedure · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Leukemia, Pediatric Cancer
Interventions: Epratuzumab, Fludarabine, Cyclophosphamide, Mesna, Infusion of NK cells, Interleukin-2; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer, Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer
Interventions: Cisplatin, Pemetrexed, Gemcitabine; Drug
Lead sponsor: Western Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Goodyear, Arizona

Conditions: Chimeric Antigen Receptor T-cell Therapy, Hematologic Malignancy
Interventions: WAYPOINT; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tobacco-Related Carcinoma
Interventions: Vaping, Biospecimen Collection, Questionnaire Administration; Other · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 21 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Colorectal Cancer
Interventions: GVAX; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Decision-Making, Patient Care, Treatment Decisions
Interventions: Influenza vaccine, Placebo; Biological · Other
Lead sponsor: University of Arkansas, Fayetteville; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Fayetteville, Arkansas • Albuquerque, New Mexico • Roanoke, Virginia

Search by objective public record fields.

Nurse Delivered Cell Phone Adherence Intervention (Pick It UP)

Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

Stem Cell Therapy for Chronic Kidney Disease

Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

CellFX System for the Treatment of Cutaneous Non-Genital Warts

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Evaluating the Human Immune Response to the JYNNEOS Vaccine

Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma

The Impact of a Polyphenol-Rich Supplement on Epigenetic and Cellular Markers of Immune Age

Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease

Glycemic Index - Variability Among Individuals

The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)

CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)

Medical Imaging and Focused Ultrasound Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)

Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

GVAX vs. Placebo for MDS/AML After Allo HSCT

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

Symptom Monitoring and Management Intervention After CAR-T

Effects of Tobacco Flavoring and Liquid Composition on Vaping Topography

Pilot Study of GVAX in Colorectal Cancer Cells

Inflammation and Medical Provider Attitudes, Cognition, and Treatment Decisions Study